|
"Genetic reprogramming of T cells for human applications" by Dr. Laurence Cooper
CEO, ZIOPHARM Oncology, Inc. and Visiting Scientist, Pediatrics – Research, MD Anderson Cancer Center |
Confirmed Speakers & Chairs include:
André Choulika, Chairman and CEO, Cellectis
Anne Altmeyer, VP Business Development, Negotiations, Baxalta
Bard Geesaman, Managing Director, MPM Capital
Beth Jacobs, Managing Partner, Excellentia Global Partners
Bibhash Mukhopadhyay, Principal, New Enterprise Associates
Boris Peaker, Managing Director, Biotechnology Equity research, Cowen Group
Brad Loncar, Chief Executive Officer, Loncar Investment, LLC
Chris Marai, Managing Director, Biotechnology Equity Research, Oppenheimer & Co. Inc.
Daniel Teper, CEO, Immune Pharmaceuticals
Dennis Purcell, Founder and Senior Advisor, Aisling Capital, LLC
Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center
Gregory Frost, Managing Director, F1BioVentures
Howard Fingert, Senior Medical Director, Internal and External Innovation for Oncology, Takeda Pharmaceuticals
James Mulé, Associate Center Director for Translational Research, Moffitt Cancer Center
Jeff Bockman, Vice President, Defined Health
Jeffrey Bacha, Chairman and Chief Executive Officer, DelMar Pharmaceuticals, Inc.
Joseph Brantuk, Vice President, Global Corporate Client Group, Nasdaq OMX
Laurence Cooper, CEO, ZIOPHARM Oncology, Inc. and Visiting Scientist, Pediatrics – Research, MD Anderson Cancer Center
Laurent Audoly, Managing Partner - Head of R&D, Pierre Fabre Fund For Innovation
Matthew Roden, UBS Equity Research, UBS
Maurice Zauderer, Founder, President & CEO, Vaccinex, Inc.
Michael Aberman, SVP, Strategy and Investor Relations, Regeneron Pharmaceuticals, Inc.
Mike Khan, Chief Medical Officer, Silence Therapeutics
Michael Woo, Director, Search & Evaluation ImmunoOncology, External Innovation, Global Research & Development, EMD Serono, Inc.
Mohamed Ragab, VP Oncology, S&E, BD, Bristol-Myers Squibb Company
Niels Emmerich, Senior Director, Head Search and Evaluation, Oncology, AbbVie, Inc.
Niranjan Sardesai, COO, Inovio Pharmaceuticals, Inc.
Paul Rennert, Founder & Principal, SugarCone Biotech, LLC
Pedro Lichtinger, Chief Executive Officer, Asterias Biotherapeutics, Inc.
Peter Hoang, Senior Vice President, Business Development & Strategy, Bellicum Pharmaceuticals, Inc.
Peter Kolchinsky, Managing Director, RA Capital Management
Robert Petit, EVP CSO, Advaxis, Inc.
Robert Stein, CSO, Agenus, Inc.
Robert Urban, Head of the Johnson & Johnson Innovation, Boston, Johnson & Johnson Innovation
Stephen Rubino, Global Head, Business Development and New Products Marketing, Cell & Gene Therapy Unit, Novartis
Steve Worland, President & Chief Executive Officer, eFFECTOR Therapeutics, Inc.
Steve Dickman, Chief Executive Officer, CBT Advisors
Stuart Barich, Managing Director, Raymond James Financial, Inc.
TBA, Nasdaq OMX
Thomas Davis, Executive Vice President, CMO, Celldex Therapeutics
Tom Farrell, CEO, Bellicum Pharmaceuticals, Inc.
William Kuziel, Director, External Scientific Affairs, Daiichi Sankyo Group
André Choulika, Chairman and CEO, Cellectis
Anne Altmeyer, VP Business Development, Negotiations, Baxalta
Bard Geesaman, Managing Director, MPM Capital
Beth Jacobs, Managing Partner, Excellentia Global Partners
Bibhash Mukhopadhyay, Principal, New Enterprise Associates
Boris Peaker, Managing Director, Biotechnology Equity research, Cowen Group
Brad Loncar, Chief Executive Officer, Loncar Investment, LLC
Chris Marai, Managing Director, Biotechnology Equity Research, Oppenheimer & Co. Inc.
Daniel Teper, CEO, Immune Pharmaceuticals
Dennis Purcell, Founder and Senior Advisor, Aisling Capital, LLC
Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center
Gregory Frost, Managing Director, F1BioVentures
Howard Fingert, Senior Medical Director, Internal and External Innovation for Oncology, Takeda Pharmaceuticals
James Mulé, Associate Center Director for Translational Research, Moffitt Cancer Center
Jeff Bockman, Vice President, Defined Health
Jeffrey Bacha, Chairman and Chief Executive Officer, DelMar Pharmaceuticals, Inc.
Joseph Brantuk, Vice President, Global Corporate Client Group, Nasdaq OMX
Laurence Cooper, CEO, ZIOPHARM Oncology, Inc. and Visiting Scientist, Pediatrics – Research, MD Anderson Cancer Center
Laurent Audoly, Managing Partner - Head of R&D, Pierre Fabre Fund For Innovation
Matthew Roden, UBS Equity Research, UBS
Maurice Zauderer, Founder, President & CEO, Vaccinex, Inc.
Michael Aberman, SVP, Strategy and Investor Relations, Regeneron Pharmaceuticals, Inc.
Mike Khan, Chief Medical Officer, Silence Therapeutics
Michael Woo, Director, Search & Evaluation ImmunoOncology, External Innovation, Global Research & Development, EMD Serono, Inc.
Mohamed Ragab, VP Oncology, S&E, BD, Bristol-Myers Squibb Company
Niels Emmerich, Senior Director, Head Search and Evaluation, Oncology, AbbVie, Inc.
Niranjan Sardesai, COO, Inovio Pharmaceuticals, Inc.
Paul Rennert, Founder & Principal, SugarCone Biotech, LLC
Pedro Lichtinger, Chief Executive Officer, Asterias Biotherapeutics, Inc.
Peter Hoang, Senior Vice President, Business Development & Strategy, Bellicum Pharmaceuticals, Inc.
Peter Kolchinsky, Managing Director, RA Capital Management
Robert Petit, EVP CSO, Advaxis, Inc.
Robert Stein, CSO, Agenus, Inc.
Robert Urban, Head of the Johnson & Johnson Innovation, Boston, Johnson & Johnson Innovation
Stephen Rubino, Global Head, Business Development and New Products Marketing, Cell & Gene Therapy Unit, Novartis
Steve Worland, President & Chief Executive Officer, eFFECTOR Therapeutics, Inc.
Steve Dickman, Chief Executive Officer, CBT Advisors
Stuart Barich, Managing Director, Raymond James Financial, Inc.
TBA, Nasdaq OMX
Thomas Davis, Executive Vice President, CMO, Celldex Therapeutics
Tom Farrell, CEO, Bellicum Pharmaceuticals, Inc.
William Kuziel, Director, External Scientific Affairs, Daiichi Sankyo Group